TGF-Beta: a Master Switch in Tumor Immunity

E-ISSN： 1873-4286|18|27|4126-4134

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.27, 2012-09, pp. : 4126-4134

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

TGF-beta Signaling in Cancer Treatment

Current Pharmaceutical Design, Vol. 20, Iss. 17, 2014-05 ,pp. : 2934-2947

Bentham Science Publishers

Access to resources Recommend Favorite

TGF-Beta Signaling Manipulation as Potential Therapy for IBD

Current Drug Targets, Vol. 14, Iss. 12, 2013-11 ,pp. : 1400-1404

Bentham Science Publishers

Access to resources Recommend Favorite

Tedisamil: master switch of nature?

By Doggrell S.A.

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 1, 2001-01 ,pp. : 129-138

Informa Healthcare

Access to resources Recommend Favorite

The Src Family Kinase Inhibitors PP2 and PP1 Block TGF-Beta1-Mediated Cellular Responses by Direct and Differential Inhibition of Type I and Type II TGF-Beta Receptors

Current Cancer Drug Targets, Vol. 11, Iss. 4, 2011-05 ,pp. : 524-535

Bentham Science Publishers

Access to resources Recommend Favorite

Growth factors as products and regulators of astrocytes: CNTF, FGF, TGF-[beta ]1-3, and GDNF

By Unsicker K. Meyer V. Flanders K.C. Wirth S.B. Rufer M. Krieglstein K. Suter-Crazzolara C.

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 223-223

Elsevier

Access to resources Recommend Favorite